Officer sold
Edwards Lifesciences's CVP, JAPAC sold $13K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Loading…
Traded Jul 10, 2026 · Filed Jul 10, 2026
Edwards Lifesciences's CVP, TAVR sold $57K of Edwards Lifesciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$56,762
Shares × reported transaction price
78 days after results of Apr 23, 2026, 13 days before results of Jul 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $92.21 on Jul 10, 2026, within 4% of its 52-week high, after a 7% rise over the previous 30 trading days
52-week range $72.65 (Oct 16, 2025) to $95.18 (Jul 6, 2026), 87% of the way up, from 251 adjusted closes. 30 trading days earlier: $86.51 on May 27, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -7.4% | -0.9% | -6.5% |
| 30 days | +1.4% | +3.1% | -1.7% |
Past results only. Not a forecast.
Edwards Lifesciences's CVP, JAPAC sold $13K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Edwards Lifesciences's CVP, JAPAC sold $819K of Edwards Lifesciences shares. Nobody planned it ahead of time.